SC 13G | 2024-02-14 | Anson Funds Management LP | Spero Therapeutics, Inc. | 4,297,599 | 8.1% | EDGAR |
SC 13G/A | 2023-02-14 | BIOTECHNOLOGY VALUE FUND L P | Spero Therapeutics, Inc. | 0 | 0.0% | EDGAR |
SC 13G/A | 2023-02-14 | Aquilo Capital Management, LLC | Spero Therapeutics, Inc. | 0 | 0.0% | EDGAR |
SC 13D/A | 2023-01-20 | GSK PLC | Spero Therapeutics, Inc. | 9,190,606 | 17.8% | EDGAR |
SC 13D/A | 2022-11-14 | GSK PLC | Spero Therapeutics, Inc. | 9,190,606 | 20.0% | EDGAR |
SC 13G/A | 2022-10-03 | Aquilo Capital Management, LLC | Spero Therapeutics, Inc. | 1,242,965 | 3.6% | EDGAR |
SC 13G | 2022-07-08 | BlackRock Inc. | Spero Therapeutics, Inc. | 690,753 | 2.1% | EDGAR |
SC 13G/A | 2022-03-09 | Aquilo Capital Management, LLC | Spero Therapeutics, Inc. | 1,642,655 | 5.1% | EDGAR |
SC 13G/A | 2022-02-14 | BIOTECHNOLOGY VALUE FUND L P | Spero Therapeutics, Inc. | 2,169,102 | 6.4% | EDGAR |
SC 13G/A | 2022-02-14 | Aquilo Capital Management, LLC | Spero Therapeutics, Inc. | 3,378,881 | 10.5% | EDGAR |
SC 13G/A | 2022-02-03 | BlackRock Inc. | Spero Therapeutics, Inc. | 1,798,777 | 5.6% | EDGAR |
SC 13G/A | 2022-01-25 | Atlas Venture Fund IX, L.P. | Spero Therapeutics, Inc. | 1,376,968 | 4.3% | EDGAR |
SC 13D/A | 2021-09-16 | GLAXOSMITHKLINE PLC | Spero Therapeutics, Inc. | 1,740,606 | 5.4% | EDGAR |
SC 13G | 2021-07-09 | PFIZER INC | Spero Therapeutics, Inc. | 2,362,348 | 7.4% | EDGAR |
SC 13D/A | 2021-02-16 | Atlas Venture Fund X, L.P. | Spero Therapeutics, Inc. | 1,031,160 | 3.8% | EDGAR |
SC 13G/A | 2021-02-16 | BIOTECHNOLOGY VALUE FUND L P | Spero Therapeutics, Inc. | 1,649,735 | 6.0% | EDGAR |
SC 13G/A | 2021-02-16 | Aquilo Capital Management, LLC | Spero Therapeutics, Inc. | 3,481,881 | 12.8% | EDGAR |
SC 13G/A | 2021-02-10 | GV 2015, L.P. | Spero Therapeutics, Inc. | 889,979 | 3.3% | EDGAR |
SC 13G/A | 2021-02-02 | Atlas Venture Fund IX, L.P. | Spero Therapeutics, Inc. | 1,376,968 | 5.1% | EDGAR |
SC 13G | 2021-02-02 | BlackRock Inc. | Spero Therapeutics, Inc. | 1,731,600 | 6.4% | EDGAR |